U.S. Markets open in 7 hrs 59 mins
  • S&P Futures

    4,129.25
    +5.75 (+0.14%)
     
  • Dow Futures

    33,949.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    12,538.00
    +22.50 (+0.18%)
     
  • Russell 2000 Futures

    1,968.00
    +2.90 (+0.15%)
     
  • Crude Oil

    75.19
    +1.08 (+1.46%)
     
  • Gold

    1,887.40
    +7.90 (+0.42%)
     
  • Silver

    22.40
    +0.16 (+0.73%)
     
  • EUR/USD

    1.0741
    +0.0010 (+0.0967%)
     
  • 10-Yr Bond

    3.6340
    0.0000 (0.00%)
     
  • Vix

    19.43
    +1.10 (+6.00%)
     
  • GBP/USD

    1.2051
    +0.0027 (+0.2254%)
     
  • USD/JPY

    132.1340
    -0.4730 (-0.3567%)
     
  • BTC-USD

    22,971.24
    +183.29 (+0.80%)
     
  • CMC Crypto 200

    527.40
    +2.27 (+0.43%)
     
  • FTSE 100

    7,836.71
    -65.09 (-0.82%)
     
  • Nikkei 225

    27,685.47
    -8.18 (-0.03%)
     

Europe Approves Novavax's COVID-19 Vaccine Booster For Adults

  • The European Commission has approved the expanded conditional approval of Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 vaccine as a homologous and heterologous booster for adults aged 18 and older.

  • The approval follows the recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use earlier this month.

  • The expanded approval was based on data from Novavax's Phase 2 trial conducted in Australia, a separate Phase 2 trial conducted in South Africa, and the UK-sponsored COV-BOOST trial.

  • The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 trials. In the COV-BOOST trial, Nuvaxovid induced a robust antibody response when used as a heterologous third booster dose.

  • In the Novavax-sponsored trials, local and systemic reactions were generally short-lived following the booster.

  • Nuvaxovid has also been authorized in Japan, Australia, and New Zealand as a booster in adults aged 18 and older and is actively under review in other markets.

  • Price Action: NVAX shares are up 1.73% at $32.27 on the last check Monday.

  • Photo by Jernej Furman via Flickr

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.